Decision Resources Research Reports

Title	Published	Price
Women's Health Series: How Have New Oral Contraceptives Changed the Market? By: Decision Resources Introduction The oral contraceptive market is mature, with a high level of competition and a stable patient population. Dozens of oral contraceptives are available worldwide; most are comparable in terms of effi \| more...	9/29/2008	$4,500.00
How to Integrate Personalized Medicine into Business Strategies By: Decision Resources Introduction A growing awareness is taking hold across the pharmaceutical industry: what was once impossible—tailoring treatment to specific groups of patients rather than to the population as a whole—is becoming possible. What is \| more...	9/24/2008	$2,250.00
Women's Health Series: Endometriosis--How Will New Therapies Compare with Current Market Leaders? By: Decision Resources Introduction Endometriosis is the cause of chronic pain and potential infertility for many women. However, no new agent to treat the disease has emerged in more than ten years, and the most common treatments employ \| more...	9/12/2008	$4,500.00
Pharmaceutical Pricing and Reimbursement in Spain, 2008 By: Decision Resources Introduction In recent years, Spain has rapidly increased its spending on healthcare, and pharmaceuticals account for a larger share of healthcare expenditures in Spain than in most other European countries. However, Spanish drug prices are \| more...	8/28/2008	$1,669.00
Key Markets in Medicare Part D By: Decision Resources Introduction Medicare Part D, the outpatient prescription drug benefit introduced in January 2006, had an immediate impact on the U.S. pharmaceutical market and now accounts for almost one-fifth of prescription drug sales. Cardiovascular diseases, metabolic \| more...	8/28/2008	$1,669.00
Evolving Trends in Licensing: Strategies for Building and Retaining Value in Biotechnology Alliances By: Decision Resources Introduction As the biotechnology industry continues to evolve and mature, many biotech companies are gaining more leverage in negotiating alliances. We analyzed recent deals and interviewed industry executives and experts to gain insight into current \| more...	8/27/2008	$1,669.00
Women's Health Series: Is There Change Ahead for the Female Infertility Market? By: Decision Resources Introduction Mounting evidence that a growing number of women are choosing to delay childbirth into their mid-tolate thirties highlights a significant opportunity for new and efficacious infertility treatments. Despite the increasing level of need, the \| more...	8/25/2008	$3,375.00
Lessons Learned from the Current Crop of Biotech Startups By: Decision Resources Introduction The initial public offering (IPO) market for biotech and specialty pharma companies has been nearly lifeless in 2008. Investment bankers are unimpressed by the performance of these companies, and money managers are reluctant to \| more...	8/18/2008	$1,669.00
How Have Safety Concerns and New Warnings Affected the Anemia Market? By: Decision Resources The recombinant erythropoietin-stimulating agents (ESAs) revolutionized treatment of severe anemias, and the anemia market prospered—until accumulating data indicated that ESA treatment may be detrimental to patient survival. Black box warnings, tighter restrictions on ESA use \| more...	6/26/2008	$1,669.00
SPECIAL REPORT: 2008 Chartbook of International Pharmaceutical Prices By: Decision Resources In an increasingly globalized pharmaceutical market, drug pricing and reimbursement policies differ markedly among countries. Payers jealously guard their authority to set prices, and both they and government authorities exert growing pressure on manufacturers to \| more...	6/26/2008	$3,375.00
SPECIAL REPORT - Fueling the Drug Discovery Engine: Biotech Investment and Business Trends By: Decision Resources Promising new therapies and drug discovery approaches are within reach, but the pharmaceutical and biotechnology industries face unprecedented scientific, business, and regulatory challenges. Can the two industries develop and exploit a mutually beneficial synergy to \| more...	6/24/2008	$3,375.00
ORPHAN DISEASE SERIES - Cystic Fibrosis: Will New Agents Emerge as First-Line Therapies? By: Decision Resources The cystic fibrosis (CF) market is poised for significant change. The next generation of CF treatments all target the central mechanism responsible for organ damage in CF. These agents, as one thought leader states, “represent \| more...	6/20/2008	$3,375.00
Improving Return on Investment in Pharmaceutical Marketing By: Decision Resources Pharmaceutical marketing is in trouble—campaigns are not as effective as they should be, and costs have spiraled out of control. Marketing expenditures are the single largest corporate investment at most pharmaceutical companies and are running \| more...	6/17/2008	$1,669.00
Pharmaceutical Pricing and Reimbursement in France, 2008 By: Decision Resources France invests heavily in maintaining its outstanding universal healthcare system. However, drug prices in France—already among the lowest in Europe—are declining as a result of tough cost-containment measures targeted primarily at pharmaceutical companies. The government \| more...	6/11/2008	$1,669.00
ORPHAN DISEASE SERIES - Glaucoma: Can Orphan-Drug Status Offer an Entry into a Mature Market? By: Decision Resources The glaucoma market has not seen any new mechanisms for treatment since the launch of prostaglandin analogues in the mid 1990s. Despite the efficacy of existing agents, glaucoma treatment still exhibits a significant level of \| more...	6/11/2008	$3,375.00
The Landscape of Companion Diagnostics: Challenges, Opportunities, and Future Trends By: Decision Resources Diagnostics can be used to identify subgroups of patients who may or may not benefit from a companion drug, who may have adverse reactions to that drug, or who may require different doses of that \| more...	6/5/2008	$1,669.00
Product Life Spans: Trends in the Quality and Staying Power of New Products By: Decision Resources The commercial potential of products in development is vitally import to the pharmaceutical industry, which is now beset with productivity concerns, looming patent expiries, and declining growth rates. Many methods are used to produce sales \| more...	6/5/2008	$1,669.00
Emerging Diagnostic Technologies for Use in Psychiatric Indications By: Decision Resources The diagnosis of psychiatric diseases is an inexact science and a slow process for physicians. No laboratory tests are available to determine the exact disease—or treatment. New diagnostic technologies could offer earlier, more specific diagnosis \| more...	5/29/2008	$1,669.00
Blood Biomarkers and Beyond: Biomarker and Diagnostic Opportunities in Cardiovascular Disease By: Decision Resources Demographic and cost data provide clear reasons for pharmaceutical industry investment in CVD biomarkers and diagnostics. CVDs are highly prevalent and potentially lethal diseases with high treatment costs; biomarkers offer the potential to decrease these \| more...	5/28/2008	$1,669.00
Pharmaceutical Pricing and Reimbursement in Japan, 2008 By: Decision Resources The pharmaceutical industry faces challenging times in the Japanese market. The government has expressed its desire to reward the development of innovative medicines and has promised more-generous price premiums for innovative drugs. At the same \| more...	5/27/2008	$1,669.00
ORPHAN DISEASE SERIES - Amyotrophic Lateral Sclerosis: Strategies for Drug Developers By: Decision Resources Only one drug is approved for the treatment of ALS, and its only benefit is a modest increase in survival time. Commercial development in this disease has been minimal, with companies being dissuaded by the \| more...	5/19/2008	$3,375.00
Pharmaceutical Pricing and Reimbursement in Italy, 2008 By: Decision Resources Italy was the only major pharmaceutical market to experience a decline in 2007.The country’s leading pharmaceutical-industry association has warned the Italian government that without a radical change in Italian pharmaceutical policy, the industry’s competitiveness in \| more...	5/7/2008	$1,669.00
Obsessive-Compulsive Disorder: Strategies to Maximize Opportunities in a Small Market By: Decision Resources Although the obsessive-compulsive disorder (OCD) market is small and OCD diagnosis rates are low, this market is characterized by substantial unmet need and commercial opportunity. Companies looking to expand their agents into this market need \| more...	5/7/2008	$1,669.00
Asia: Threat or Opportunity? By: Decision Resources Asian economic might is growing, and the Asian pharmaceutical markets and industry are growing along with it. Western pharmaceutical companies have become very interested in entering Asian markets and taking advantage of the opportunities they \| more...	5/5/2008	$1,669.00
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the First Quarter of 2008 By: Decision Resources Spending on prescription drugs continues to grow in worldwide markets—but not as fast as other healthcare expenditures. Consequently, the pharmaceutical industry’s relatively modest share of total healthcare costs— less than 15% in most mature markets—is \| more...	4/30/2008	$1,669.00
Title	Published	Price

< prev 1 2 3 4 5 6 7 8 9 10 next >

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/22/2009 - 4